Clinical Chemistry
October 7, 2011
Andrea E. Schwaninger, Markus R Meyer, Allan J. Barnes et al.
33 citations
BACKGROUND 3,4-Methylendioxymethamphetamine (MDMA) is excreted in human urine as unchanged drug and phase I and II metabolites. Previous urinary excretion studies after controlled oral MDMA administration have been performed only after conjugate cleavage. Therefore, we investigated intact MDMA glucuronide and sulfate metabolite excretion. METHODS We used LC–high-resolution MS and GC-MS to...
Therapeutic Drug Monitoring
October 1, 2011
Allan J. Barnes, Karl B. Scheidweiler, Erin A. Kolbrich-Spargo et al.
22 citations
Oral fluid monitoring efficiently detects single, recreational 70-150 mg of MDMA use for 1-2 days. These controlled administration data provide a scientific basis for interpreting MDMA oral fluid test results.
Biochemical Pharmacology
September 29, 2011
Andrea E. Schwaninger, Markus R Meyer, Allan J. Barnes et al.
23 citations
The R- and S-enantiomers of racemic 3,4-methylenedioxymethamphetamine (MDMA) exhibit different dose-concentration curves. In plasma, S-MDMA was eliminated at a higher rate, most likely due to stereoselective metabolism. Similar data were shown in various in vitro experiments. The aim of the present study was the in vivo investigation of stereoselective elimination of MDMA's phase I and phase II...
Journal of Analytical Toxicology
October 1, 2009
T. T. Abraham, Allan J. Barnes, Richie H. Lowe et al.
56 citations
3,4-Methylenedioxymethamphetamine (MDMA), or ecstasy, is excreted as unchanged drug, 3,4-methylenedioxyamphetamine (MDA), and free and glucuronidated/sulfated 4-hydroxy-3-methoxymethamphetamine (HMMA), and 4-hydroxy-3-methoxyamphetamine (HMA) metabolites. The aim of this paper is to describe the pattern and timeframe of excretion of MDMA and its metabolites in urine. Placebo, 1.0 mg/kg, and 1.6...